reSee.it - Related Video Feed

Joe Rogan and Aubrey de Grey discuss life extension and anti-aging research. De Grey, a researcher formerly affiliated with Cambridge, now leads the SENS Research Foundation in California, which has a $5 million annual research budget. He emphasizes that aging is not a single phenomenon but a collection of interacting issues, requiring a "divide and conquer" strategy for effective medical intervention. De Grey notes that while there are many breakthroughs in aging research, they are often technical and not widely understood. He highlights the need for better collaboration across different fields of aging research, as current funding structures create silos that hinder progress. He argues that aging should be viewed as a disease, stating that diseases of old age are side effects of accumulated damage over time. De Grey believes the solution lies in developing therapies to repair this damage, rather than treating diseases in isolation. He mentions promising areas of research, such as stem cell therapy for Parkinson's disease and targeting atherosclerosis through engineered bacteria to break down oxidized cholesterol. De Grey expresses concern about the limited funding for aging research, suggesting that increasing the budget could significantly accelerate progress. He also addresses philosophical questions about longevity, arguing that the focus should be on improving health rather than merely extending life. He believes that technological advancements could help address potential societal issues related to overpopulation and resource management. Overall, de Grey is optimistic about the future of aging research but stresses the urgency of developing effective therapies to combat the aging process and improve quality of life.

Focusing on well-being and health resets bodily systems, reducing inflammation and improving metabolism. Weight loss should be a side effect of health, not the primary goal. The idea that all calories are equal is misleading; different foods have varying effects on the body. For instance, low-carb diets can enhance metabolism and improve health markers compared to low-fat diets. Phytochemicals in plants, like those in broccoli, play crucial roles in detoxification and health. Himalayan Tartary buckwheat is highlighted for its unique compounds that rejuvenate the immune system. The conversation around meat is complex; context matters, as meat can be part of a healthy diet when consumed with nutrient-rich foods. Resistance training is superior for heart health and metabolic efficiency compared to cardiovascular exercise. Chronic inflammation is linked to many diseases, and lifestyle changes can mitigate these risks. A holistic approach addressing root causes of health issues is essential, rather than treating conditions in isolation.

David Sinclair lays out a personal narrative of why aging is a solvable problem, beginning with a pivotal memory of his Hungarian grandmother and a childhood realization that aging and death aren’t inevitable. He explains his long-term view that aging is a central, modifiable biological process, not a natural fate, and he describes a research program aiming to reset the body's age by reinstating a youthful epigenetic state. The conversation then moves into practical demonstrations from his lab, including work on reversing age in cells, extending lifespan in animals, and the first human trial aimed at restoring function in the eye. Sinclair emphasizes safety and cautious steps in translating animal and primate work to humans, noting that age reversal could first appear as treatments for age-related diseases rather than a blanket rejuvenation, with the eye model serving as a safer starting point. The discussion expands to how aging is driven by epigenetic information and how the body maintains identity through gene expression; aging is framed as an identity crisis in aging cells caused by erasure of epigenetic marks and mislocalization of the proteins that control which genes are active. He argues that turning back this epigenetic clock could simultaneously address multiple diseases, including cancer, neurological disorders, and degenerative conditions, because aging underpins these illnesses. The podcast also tackles lifestyle choices, such as diet, fasting, exercise, sleep, and stress management, highlighting that behavior strongly modulates aging through cellular stress responses and metabolic pathways. They discuss the feasibility and timeline for broad access to such medicines, the regulatory and geopolitical landscape, and the societal implications of longer, healthier lives. The tone remains exploratory and forward-looking, with Sinclair acknowledging remaining uncertainties, the need for rigorous trials, and the ethical and economic questions that will accompany a future in which aging can be slowed, paused, or reversed.

David Sinclair asserts that there is no biological limit to human lifespan, emphasizing that aging is primarily a "software problem" that can be addressed through biological reprogramming. He highlights that lifestyle choices account for 93% of longevity, with genetics only contributing 7%. Sinclair advocates for preventative health measures, noting that many diseases, including heart disease and cancer, are largely avoidable with advanced technology and lifestyle changes. He discusses the potential of new treatments, such as a vaccine against the PCSK9 enzyme to lower cholesterol affordably. Sinclair emphasizes the importance of a longevity mindset, which includes having goals and maintaining social connections. He shares personal anecdotes about his father's transformation after adopting a longevity-focused lifestyle. The conversation touches on the rapid advancements in aging research, with Sinclair noting that the field is attracting younger scientists passionate about longevity. He believes that within ten years, age-reversal treatments will be accessible to the public. Sinclair concludes by arguing that extending healthy life is a moral obligation, allowing individuals to choose their lifespan while contributing positively to society.

In this episode of the Huberman Lab podcast, Dr. Andrew Huberman interviews Dr. David Sinclair, a professor of genetics at Harvard Medical School, focusing on the biology of aging and interventions to slow or reverse aging. Sinclair views aging as a disease rather than a natural process, emphasizing that it can be addressed through various interventions, including behavioral changes, nutrition, and supplementation. Sinclair discusses the concept of "longevity" versus "anti-aging," explaining that while longevity refers to extending life, anti-aging has been misused in popular culture. He highlights the importance of understanding aging as a disease that contributes to many other health issues, such as heart disease and Alzheimer's. Sinclair's research identifies several "hallmarks" of aging, with a significant focus on the epigenome, which controls gene expression and influences cellular aging. The conversation delves into practical tools for combating aging, including dietary practices like intermittent fasting, which Sinclair advocates for its benefits in regulating insulin and glucose levels. He explains that elevated blood sugar and insulin can accelerate aging, while fasting can activate longevity genes, particularly sirtuins, which play a crucial role in cellular health. Sinclair shares his personal regimen, which includes skipping breakfast, taking supplements like NMN (Nicotinamide Mononucleotide) and resveratrol, and practicing intermittent fasting. He emphasizes the importance of measuring biological age through blood tests and other metrics to track health and optimize longevity strategies. The discussion also touches on the role of exercise, the impact of obesity on NAD levels, and the potential benefits of cold exposure. Sinclair mentions the significance of keeping inflammation low, particularly in the hypothalamus, which regulates aging and reproductive health. Sinclair's upcoming projects include a new podcast focused on aging and a biological age test that aims to democratize access to health metrics. He expresses optimism about the future of public education in science, highlighting the need for trusted sources of information in a world filled with misinformation. Overall, the episode provides insights into the mechanisms of aging, practical strategies for improving health, and the importance of scientific communication in promoting longevity.

David Sinclair discusses the potential for reversing aging, emphasizing that aging is a loss of information rather than mere physical damage. He believes there is no upper limit to human lifespan, citing examples from other species that live significantly longer. Sinclair's research focuses on epigenetics, revealing that every cell contains a backup copy of information that can be accessed to rejuvenate tissues. He highlights recent breakthroughs in resetting biological age in mice and the promise of similar therapies for humans, particularly in reversing conditions like blindness. Sinclair predicts that within the next two years, human clinical trials for age reversal will begin. He stresses the importance of lifestyle choices in maintaining a youthful biological age and mentions ongoing research to develop affordable age-reversal therapies. Sinclair's work aims to make these advancements accessible to all, not just the wealthy, and he is optimistic about the future of longevity science.

American healthcare is in crisis, but there is a path to prevention focused on the major age-related diseases: cancer, heart disease, and Alzheimer's. Eric Topol's book, "Super Agers," explores the potential for extending health spans by preventing these diseases rather than reversing aging. Key insights include the importance of lifestyle factors and the role of AI in analyzing health data. Topol emphasizes that many age-related diseases are preventable through lifestyle changes and emerging treatments, including personalized vaccines and new drug classes like GLP-1s for obesity. He advocates for a shift from a reactive to a preventive healthcare model, utilizing polygenic risk scores and organ clocks to tailor individual care. The future may see healthier aging populations, with fewer individuals suffering from major diseases, as preventive measures become standard practice.

In the discussion, Dr. Andrew Steele explores the complexities of aging and the potential for its cure, emphasizing the ongoing computational revolution in biology. He defines aging both statistically, as the increasing risk of death over time, and biologically, through the hallmarks of aging, which are cellular and molecular changes that accumulate with age. Steele argues that there is a cultural blind spot regarding the idea of curing aging, suggesting that it should be normalized as a target for medicine. He posits that addressing aging may be more effective than tackling individual diseases like cancer and heart disease, as these diseases are often symptoms of the aging process itself. Steele highlights that many diseases associated with aging share common biological mechanisms, making aging a root cause worth targeting. The conversation touches on the evolutionary perspective of aging, suggesting that death and aging may serve adaptive purposes in evolution, allowing for genetic diversity and adaptation to changing environments. Steele discusses the role of calorie restriction in extending lifespan, noting that while it has been shown to work in various organisms, its effects on humans remain uncertain. Steele highlights the importance of research into aging, advocating for public support to drive scientific advancements. He discusses the potential of therapies targeting senescent cells, which could improve health and longevity. The conversation also addresses the philosophical implications of extending life, questioning the meaning of existence and the moral duty to pursue longevity. Finally, Steele expresses optimism about the future of aging research, suggesting that breakthroughs could arrive in time for current generations, potentially leading to healthier, longer lives. He encourages listeners to engage with the topic and support research efforts, emphasizing that every year lived increases the chance of benefiting from future medical advancements.

Andrew Huberman and Dr. David Sinclair discuss aging, defining it as a disease rather than an inevitable process, arguing that it's the primary cause of most chronic illnesses. Sinclair posits that aging is fundamentally a loss of information within cells, akin to "scratches on a CD," primarily affecting the epigenome—the system controlling gene expression. These "scratches" are caused by factors like DNA damage (e.g., X-rays, sun exposure) and cellular stress, leading to cells losing their identity and function. Interestingly, periods of rapid development, like early life, show accelerated biological aging according to epigenetic clocks. Sinclair emphasizes that while genetics play a role, 80% of longevity is influenced by epigenetic information, which can be positively modified by lifestyle. A key actionable protocol is intermittent fasting, which activates longevity genes called sirtuins by keeping insulin and insulin-like growth factor levels low. This contrasts with constant feeding, which keeps these protective genes inactive. Skipping a meal daily is recommended, with longer fasts (2-3 days) triggering deeper cellular cleansing processes like chaperone-mediated autophagy, which has shown significant lifespan extension in mice. The conversation also covers supplementation, with Sinclair discussing his personal use of NMN to boost NAD levels, which are crucial for sirtuin activity. He highlights the importance of personalized medicine and tracking biomarkers like HbA1c (average glucose) and C-reactive protein (CRP) for inflammation, a strong predictor of cardiovascular disease and mortality. Exercise, particularly for maintaining muscle mass and hormone levels, is also crucial. Sinclair shares groundbreaking research on rejuvenating the female reproductive system in old mice using NMN, challenging conventional biological understanding and suggesting the body's remarkable capacity for repair and rejuvenation.

Dax Shepard hosts David Sinclair, an Australian biologist and professor of genetics known for his research on aging and longevity. Sinclair discusses his background, including his PhD from the University of New South Wales and his work at Harvard Medical School since 1999. He emphasizes the importance of longevity research, distinguishing it from anti-aging, which he associates with snake oil salesmen. Sinclair believes that understanding aging can lead to significant advancements in medicine, arguing that aging should not be accepted as a natural process but rather as a condition that can be treated. Sinclair explains that traditional medicine focuses on diseases rather than the aging process itself, which he sees as a missed opportunity. He discusses the role of the epigenome in aging, suggesting that it deteriorates over time, leading to inefficient gene expression. Sinclair's lab has made breakthroughs in reversing aging in mice, using a combination of embryonic genes to reset cellular age. He mentions the potential for this technology to be applied to humans, with hopes of clinical trials in the near future. The conversation touches on the societal implications of extended lifespans, including ethical dilemmas and the potential for increased suicide rates if people feel trapped in a long life. Sinclair acknowledges the need for discussions about the consequences of longevity research, including economic impacts and the potential for societal changes in perceptions of age and wisdom. Sinclair expresses optimism about the future of aging research, predicting breakthroughs within the next five years that could lead to significant advancements in health and longevity. He emphasizes the importance of public discourse on these topics, advocating for transparency and direct communication between scientists and the public.

In this Relentless episode, host Ti Morse talks with Lada Nuja, founder and CEO of General Control, about the frontier of aging medicine through epigenetic technologies. Nuja shares how she shifted from theoretical physics to biomedicine, driven by a belief that aging is not a single problem but a cascade of interconnected processes. She explains that aging’s complexity makes traditional single-target drugs insufficient and describes her vision for a new therapeutic modality that can rewrite the epigenetic program of cells. The conversation also covers practical realities of biotech entrepreneurship, including the harsh funding landscape for aging research, the role of government grants, and the need for a fast, accountable path from idea to human data. Nuja emphasizes the importance of measuring biological aging through human data, rather than relying solely on animal models, and argues that epigenetic editing could provide durable cures rather than temporary band-aids. She contrasts her approach with conventional drug development, highlighting how the field often targets downstream effects and why she believes a “one-and-done” strategy, if safely implemented, could be transformative for diseases of aging. Nuja draws on the Iobiotech example—an European startup acquired by AstraZeneca for about a billion dollars—to illustrate how accelerated access to human data, especially via China, can compress development timelines. She discusses the economics and incentives that shape biotech, noting the problematic funding bias toward diseases like Alzheimer's and the scarcity of patient-wide, aging-focused investment in the United States. The interview also explores the decision-making behind building a company: starting with tool-building and funding early-stage science through programs like Impetus, moving toward an engineering-first, risk-managed path to a marketable asset, and preparing for endgame exits with pharma partners. Throughout, Nuja emphasizes speed, disciplined execution, and a willingness to take calculated risks, arguing that a small, nimble team can outperform bloated ventures in a field where the clock is relentless and the patient is future generations. The dialogue touches on personal resilience and the immigrant experience driving Nuja’s ambition. She recounts growing up in eastern Ukraine, the upheaval of war, and the long journey to the United States, including multiple college rejections before finally establishing herself in the Bay Area biotech scene. The episode ends with reflections on ambition, longevity, and leadership: Nuja contends that living longer will demand new social and economic structures, and she asserts a philosophy of purposeful risk-taking, continuous learning, and prioritizing the patient’s future as the ultimate metric of success.

Dr. Mark Hyman discusses the critical role of inflammation in age-related diseases, asserting that conditions like heart disease, cancer, and diabetes stem from chronic inflammation. He emphasizes that aging is being redefined as a disease, with a growing focus on longevity research fueled by significant funding. Hyman highlights the importance of understanding biological aging, which can be influenced by lifestyle choices, rather than merely treating diseases as they arise. His book, "Young Forever," explores the Hallmarks of Aging, including mitochondrial dysfunction and DNA damage, advocating for a functional medicine approach that addresses underlying causes. Hyman notes that food is a major modifier of health, capable of either enhancing or degrading biological function. He promotes a balanced intake of protein, particularly emphasizing the importance of high-quality animal protein for muscle maintenance, which is vital for longevity. Hyman also discusses advanced therapies like hyperbaric oxygen and hormesis, which activate the body's innate healing systems. He advocates for a holistic approach to health, integrating lifestyle changes, dietary interventions, and emerging medical innovations. Finally, he highlights the need for updated nutrition policies in the U.S. to reflect current scientific understanding and improve public health outcomes.

David Sinclair discusses the concept of aging, emphasizing that there is no biological law mandating aging and that many centenarians often neglect their health. He expresses a desire to alleviate the suffering caused by aging, noting that over 100,000 people die daily from age-related issues. Sinclair highlights the economic burden of aging, estimating that slowing down aging by just one year could save the U.S. $86 trillion over three decades, which could be redirected towards education and healthcare. Aging, he explains, is linked to the loss of epigenetic information that regulates gene expression. This disruption leads to diseases and dysfunctions, which are often treated only at their end stages rather than addressing the root cause—aging itself. Sinclair uses the analogy of a scratched DVD to describe how aging affects our genetic information, suggesting that recent research indicates potential methods to "polish" these scratches. Sinclair advocates for lifestyle changes to reduce biological age, such as fasting, which activates epigenetic regulators known as sirtuins. He explains that adversity, including fasting and dietary choices, can stimulate these genes, promoting longevity. He recommends a Mediterranean diet rich in plants, which has been shown to activate longevity pathways. He also discusses the importance of exercise, emphasizing that even minimal aerobic activity can yield significant health benefits. Sinclair notes that psychological stress negatively impacts longevity, while a positive outlook and sense of purpose can contribute to a longer life. On supplements, Sinclair takes NMN, resveratrol, and Athletic Greens to support his health. He believes that while supplements can aid longevity, they should complement a healthy lifestyle rather than replace it. He mentions ongoing research into cellular reprogramming and potential breakthroughs that could extend human lifespan significantly. Sinclair concludes that while there may be limits to human lifespan, advancements in science and lifestyle choices can potentially allow individuals to live much longer, healthier lives. He encourages proactive health management and emphasizes the importance of making informed lifestyle choices to enhance longevity.

The aging process is often misunderstood, with common misconceptions about the potential for a cure for aging. Current research focuses on compressing morbidity at the end of life, aiming to minimize the time spent with diseases to enhance quality of life. Key factors influencing healthy aging include regular physical exercise, a balanced diet—particularly the Mediterranean diet—adequate sleep, and maintaining social connections and a sense of purpose. Stress management and creativity also play significant roles in biological health. Indicators of healthy aging include blood pressure, lipid profiles, hemoglobin A1c, VO2 max, and grip strength. Regular health screenings are crucial, as many individuals are unaware of conditions like high blood pressure or diabetes. Lifestyle choices significantly impact aging, with 80% of aging influenced by behavior rather than genetics. The Rosetta study highlights the importance of social engagement and community in longevity, showing that relationships and social structures contribute to better health outcomes. Recent studies indicate that adverse childhood experiences can affect biological aging, but positive changes in adulthood can mitigate these effects. Cold water exposure is discussed as a beneficial practice for stimulating biological responses. Ultimately, understanding the science behind aging can motivate individuals to adopt healthier lifestyles, emphasizing the importance of diet, exercise, and social connections in promoting longevity and well-being.

In this episode of the Drive podcast, host Peter Attia interviews Ned David, co-founder and president of Unity Biotechnology, focusing on the science of cellular senescence and its implications for longevity and healthspan. They discuss the concept of senescence, which refers to the state where cells stop dividing due to stress and accumulate with age, contributing to various age-related diseases. Ned explains that aging is not a fixed process but rather a flexible one, influenced by various biochemical systems that can be manipulated. He highlights three principles: aging is malleable, nature has control knobs that can be turned, and these knobs can be targeted for therapeutic interventions. They explore examples from nature, such as the differing lifespans of similar species, to illustrate the potential for extending healthspan through scientific advancements. Ned shares his background as a serial entrepreneur in biotechnology, detailing his experiences in developing FDA-approved compounds and how these experiences shaped his approach to Unity. He emphasizes the importance of understanding the biological mechanisms of aging, particularly cellular senescence, and how it can be targeted to improve health outcomes. The conversation shifts to Unity's research on senolytic therapies, which aim to eliminate senescent cells to alleviate age-related conditions like osteoarthritis. Ned describes their findings from animal studies showing that removing senescent cells can lead to significant improvements in health and lifespan. They discuss the implications of these findings for human health, particularly in treating osteoarthritis, a condition that affects many older adults. Ned outlines the results of Unity's phase one clinical trial, which demonstrated that a single injection of their senolytic drug significantly reduced pain in patients with osteoarthritis. He notes that the drug targets senescent cells by inhibiting specific pathways, leading to their selective death without harming healthy cells. The discussion touches on the potential for this approach to extend beyond osteoarthritis to other age-related diseases, including Alzheimer's and cardiovascular diseases. Throughout the episode, Ned emphasizes the importance of collaboration and learning from others in the field, as well as the need for a clear understanding of the risks involved in drug development. He encourages aspiring scientists and entrepreneurs to pursue their passions while remaining open to the possibilities of both academic and entrepreneurial pathways. In conclusion, the conversation highlights the exciting potential of targeting cellular senescence as a strategy for improving healthspan and longevity, with Unity at the forefront of this innovative research.